Contrast Agents and Safety

Contrast agents are used in orthopaedic imaging to enhance tissue differentiation and improve diagnostic accuracy. Iodinated contrast is used for CT, fluoroscopy and conventional arthrography; gadolinium-based contrast agents (GBCAs) are used for MRI. Contrast-enhanced imaging is not routinely required for most musculoskeletal conditions, but it plays a critical role in tumour staging, infection assessment, vascular evaluation, arthrography and post-operative assessment.

Why the surgeon needs this. Orthopaedic patients frequently require contrast-enhanced imaging, and the operating surgeon may need to manage a contrast reaction in the perioperative setting. Contrast pharmacology, reaction management and renal safety are therefore essential knowledge for all orthopaedic surgeons, not just radiologists.

Iodinated contrast. Iodinated contrast works by absorbing X-rays, a consequence of the high atomic number of iodine (Z=53). Modern agents are non-ionic and low-osmolar (iohexol, iopamidol), which significantly reduced reaction rates compared with the older ionic high-osmolar agents. Iodinated contrast is excreted renally and is the agent associated with contrast-induced nephropathy (CIN). Its orthopaedic applications:

• CT angiography
• Contrast-enhanced tumour assessment
• CT arthrography

Gadolinium contrast. Gadolinium is a paramagnetic metal that shortens the T1 relaxation time of nearby water molecules, so the tissue where it accumulates becomes T1-bright. GBCAs are chelated, the ion bound inside a molecular cage, to reduce toxicity. The key safety concern is nephrogenic systemic fibrosis (NSF) in severe renal impairment (eGFR less than 30), and modern macrocyclic agents (gadobutrol, gadoterate) have the lowest NSF risk because their chelate structure is more stable. Its orthopaedic applications:

• MR arthrography
• Tumour enhancement
• Infection assessment
• Post-operative evaluation

Six questions, asked before any contrast is administered.

What the reaction is. Iodinated contrast reactions are anaphylactoid: direct mast cell degranulation, not a true IgE-mediated allergy. Two things follow. They can occur on first exposure, and they cannot be predicted by skin testing.

View larger

Quote the rate for the agent you are actually using. The "5 to 10 percent" mild-reaction figure that circulates in vivas belongs to the high-osmolar ionic era, when the total adverse reaction rate was 12.66 percent. With the non-ionic low-osmolar agents that are now standard, the total rate across 168,363 examinations was 3.13 percent, of which 0.04 percent were severe, so the modern figures are roughly a quarter of the old ones, and an examiner quoting 10 percent is quoting an obsolete agent class.

Adrenaline first. Adrenaline is always the first-line treatment for anaphylaxis: it reverses bronchospasm, supports the blood pressure and reduces oedema. Antihistamines and corticosteroids are second-line adjuncts and should never delay it. All moderate and severe reactions require a minimum observation period and documentation for future reference.

The rest of the resuscitation. Stop the contrast infusion and call for help early. Give high-flow oxygen via mask and a salbutamol nebuliser for bronchospasm, and consider intubation if the airway is compromised. Secure large-bore IV access, give a rapid IV saline bolus of 500 mL to 1 L, and position the hypotensive patient supine with the legs elevated (Trendelenburg). The second-line drugs are promethazine 25 mg IV or chlorpheniramine 10 mg IV, and hydrocortisone 200 mg IV. Monitor continuously throughout: ECG, SpO2 and blood pressure.

Adrenaline dosing is weight- and age-banded, and 0.5 mg is the adult dose only. A paediatric patient having a contrast-enhanced CT is not rare in orthopaedics, and the wrong dose in either direction is dangerous. All doses below are 1:1000 intramuscular into the anterolateral thigh, repeated after 5 minutes if there is no improvement:

By weight the equivalent is 10 micrograms/kg IM. Intravenous adrenaline is a different drug in practice. It is given only by those trained to use it, with continuous cardiac monitoring, in 50 microgram boluses of the 1:10,000 dilution. Giving the 1:1000 intramuscular dose intravenously is a recognised cause of fatal arrhythmia and myocardial ischaemia, which is why the ampoule strength should be stated out loud when it is drawn up.

Confirming it was anaphylaxis afterwards: mast cell tryptase. Take three timed samples: immediately once resuscitation allows, at 1 to 2 hours, and a baseline at 24 hours or later once the patient has recovered. A rise and fall across the series supports mast cell degranulation and is what an allergy clinic needs; a single sample is close to uninterpretable because the baseline varies between people. Never delay resuscitation to take blood, and note that a normal tryptase does not exclude anaphylaxis, since it is commonly normal in reactions without hypotension.

Premedication for the patient with a prior reaction. A history of contrast reaction raises the risk of a future reaction 5-6 times. Premedication reduces the incidence and severity of subsequent reactions but does not eliminate the risk entirely, and it is most effective when the full protocol, all three steroid doses, is completed. The standard protocol, widely used internationally in the ACR/ESUR style:

• Prednisolone 50mg orally at 13h, 7h, and 1h before contrast administration
• Promethazine 25mg orally 1h before contrast, OR cetirizine 10mg orally 1h before
• Alternative: hydrocortisone 200mg IV 1h before, for emergency or urgent cases where oral dosing is not feasible

What premedication does not do. Even with premedication, breakthrough reactions occur, so emergency equipment must always be available, and every radiology department should have a documented protocol for managing contrast reactions. If the previous reaction was severe anaphylaxis, consider whether the imaging is truly essential and whether a non-contrast alternative could provide the needed information.

Seafood allergy and iodine. There is no cross-reactivity between iodinated contrast and shellfish allergy. The myth of "iodine allergy" is unfounded: iodine is an essential element, not an allergen, and shellfish allergy is to tropomyosin protein, not iodine.

A biphasic reaction is the recurrence of anaphylaxis after it has apparently resolved, without any further exposure to the trigger. It is the entire reason a patient is kept under observation once a severe reaction has settled, and it is why a discharge decision is a clinical judgement rather than a fixed number of hours.

How common. The figure most often quoted in vivas, "up to 20 percent", comes from small early case series and is a substantial overestimate. Pooling 27 observational studies and 4,114 patients with anaphylaxis gives 192 biphasic reactions, 4.7 percent, with a median onset at 11 hours and a range from 12 minutes to 72 hours. That single figure explains why a fixed observation period cannot be right for everyone: a median of 11 hours sits well beyond the 4 to 6 hours most departments use.

Who is at risk. The same pooled data identify who is actually at risk, which is what should drive the decision, and a contrast reaction does not sit in the low-risk category. This is level 3 evidence, a systematic review and meta-analysis of observational studies with substantial heterogeneity for the hypotension estimate.

• Presenting with hypotension roughly doubles the risk (pooled odds ratio 2.18, 95% CI 1.14 to 4.15). A patient who collapsed after contrast is therefore in the higher-risk group, not the reassuring one
• An unknown or unidentified trigger raises risk (odds ratio 1.72, 95% CI 1.0 to 2.95), while a food trigger lowers it (odds ratio 0.62)

Definition. CIN is an acute decline in renal function, a rise in serum creatinine of 25% or more, or 44 micromol/L or more above baseline, occurring within 48-72 hours of iodinated contrast administration, in the absence of another cause. It is detected by checking the creatinine 48-72 hours after contrast.

Hydration, and its limits. Isotonic saline is the only prophylaxis still endorsed, and the endorsement is for eGFR below 30, not above it. In randomised data on patients with eGFR 30-59 receiving intravenous contrast, withholding prophylactic hydration was non-inferior to giving it (AMACING), and neither sodium bicarbonate nor N-acetylcysteine is any better than plain saline (PRESERVE). Below eGFR 30 the evidence is thinner, because that group was excluded from those trials, so the regimen in the table stands for that group. Renal anxiety should not delay a clinically essential scan.

Natural history. CIN is typically transient: creatinine peaks at 3-5 days and returns to baseline within 7-14 days in the majority of cases. A small proportion of patients, particularly those with severely impaired baseline renal function, may develop persistent renal impairment or require temporary dialysis. The risk of permanent dialysis-dependent renal failure from CIN is very low in the general population but clinically significant in high-risk patients (eGFR less than 15, diabetic nephropathy, heart failure).

Two iodinated-contrast hazards fall to the orthopaedic team more often than anaphylaxis does, and neither is a renal problem.

Extravasation. Extravasation of iodinated contrast into the soft tissues of the arm complicates roughly 0.1 to 1 percent of power-injected CT studies. It matters here because the feared endpoint is compartment syndrome, and the referral usually lands with orthopaedics.

Most extravasations are benign and are managed conservatively. Stop the injection, elevate the limb above the heart to encourage reabsorption, and apply a cold compress. Hyaluronidase and steroid injection are not routinely indicated. Document the estimated volume, since larger volumes carry more risk, though volume alone is a poor predictor and a small extravasation in a tight compartment can be worse than a large one in a lax forearm.

The thyroid. A standard contrast dose delivers an enormous iodine load, orders of magnitude above the daily dietary requirement, and two consequences follow.

It can precipitate thyrotoxicosis in a patient with Graves' disease or an autonomously functioning nodule (the Jod-Basedow phenomenon), typically appearing weeks after the study rather than immediately. Ask about thyroid disease before elective contrast in an at-risk patient, and warn them what to look out for.

It blocks radioiodine uptake. A patient who may need a radioiodine scan or radioiodine therapy should not receive iodinated contrast beforehand, because the thyroid will be saturated and the study or treatment is wasted; typically a delay of about 6 weeks to 2 months is needed. This is a scheduling error that is easy to make and expensive to correct, so it is worth asking about planned nuclear medicine studies when contrast is requested. Neither effect applies to gadolinium.

Nephrogenic systemic fibrosis. NSF is a potentially fatal fibrosing condition affecting the skin, joints and internal organs, caused by gadolinium in severe renal impairment. The risk is almost exclusively in patients with an eGFR less than 30, and the culprit is free, unchelated gadolinium released from the contrast agent. That risk is what drives the avoidance of the high-risk linear agents and the eGFR-based screening before any gadolinium is given.

View larger

Why the chelate structure drives the risk. Linear (open-chain) chelates hold the gadolinium ion less tightly, so during prolonged retention in severe renal impairment they release more free (toxic) gadolinium, which triggers NSF. Macrocyclic chelates fully encage the ion in a rigid ring and release almost none. This is why the Group II macrocyclics are preferred whenever gadolinium is essential, and why the European regulator suspended most Group I linear agents in 2017.

The ACR groups. The ACR classifies gadolinium-based contrast agents into three groups by their association with NSF. The numbering is counter-intuitive and is a standing trap: Group I is the HIGHEST-risk (linear) group, not the safest. Say "macrocyclic" out loud before saying a group number, and the error becomes hard to make.

Contrast media safety is governed by broadly convergent international guidance, with non-ionic low-osmolar iodinated agents and macrocyclic gadolinium agents now standard worldwide. The main areas of genuine divergence are the eGFR thresholds for renal precautions and the role of premedication.

Global Epidemiology

• Iodinated contrast acute reactions: mild 0.5-3% and severe approximately 0.04% with low-osmolar agents (down from approximately 0.22% with the older high-osmolar agents).
• Gadolinium acute reactions are rarer (roughly 0.04-0.07% overall); confirmed NSF is now exceedingly rare since linear agents were restricted, with virtually no unconfounded cases reported after macrocyclic-only exposure.
• Contrast-associated AKI: historically reported in 2-25% of at-risk patients, but contemporary controlled data (propensity-matched and RCT) suggest the true attributable risk from modern IV contrast is much lower than once believed, especially above eGFR 30.

Side-by-Side Guideline Comparison

High- vs Limited-Resource Practice Variation

• Well-resourced settings: macrocyclic gadolinium exclusively, point-of-care creatinine, structured premedication and anaphylaxis pathways, and routine post-contrast monitoring.
• Limited-resource settings: high-osmolar ionic agents may still be used for cost reasons (higher reaction rates), eGFR may be unavailable before urgent imaging, and adrenaline or resuscitation equipment may not be immediately at the contrast injection site — the single most important safety gap to close.
• Universal minimum standard everywhere: adrenaline, oxygen, IV access and trained staff must be immediately available wherever contrast is injected, regardless of setting.